News
-
-
-
-
PRESS RELEASE
Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Aurisco Pharmaceutical, a global Oligonucleotide and Peptide manufacturer, becomes the first generic oligonucleotide API manufacturer in the world to pass USFDA inspection. The inspection sets a new standard for safe and affordable oligonucleotides -
-
-
PRESS RELEASE
EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Brockhaus Technologies AG reports preliminary revenue of €13.4 million and adjusted EBITDA of €-0.5 million for H1 2026, with forecast for continuing operations unchanged -
-
PRESS RELEASE
Voltalia annonce un investissement envisagé par la SFI pouvant atteindre 120 millions d’euros en actions de préférence de sa filiale VMI, convertibles en actions ordinaires Voltalia, sous réserve de l’approbation des actionnaires
Voltalia annonce un investissement envisagé par la Société Financière Internationale pouvant atteindre 120 millions d’euros en actions de préférence de sa filiale VMI, sous réserve de l’approbation des actionnaires -
PRESS RELEASE
Voltalia announces an upcoming investment by the International Finance Corporation of up to €120 million in preferred shares of Voltalia’s subsidiary, convertible in ordinary shares of Voltalia, subject to shareholders’ approval
Voltalia announces €120 million investment by International Finance Corporation in Voltalia Management International, subject to shareholder approval. Investment to support renewable energy assets